COVID-19 Updates

Here you will find all the latest news posts from Olink related to the COVID-19 pandemic.

Current number of planned/ongoing studies using Olink = 59

For additional info, visit us on LinkedIn

Questions or comments?


  • Longitudinal proteomic profiling of high-risk patients with COVID-19

    Pre-print now available: Markers of severity and predictors of fatal disease identified in high-risk patients with COVID-19 Background/design End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19, and in this study, longitudinal protein profiling with five dif...
  • Plasma ACE2 and risk of death or cardiometabolic diseases

    Large epidemiological study of association of plasma ACE2 levels with CVD risk Cardiovascular diseases have been one of the most studied comorbidities in connection with COVID-19. A study by researchers at Hamilton Health Sciences in Ontario, Canada has examined the levels of the S...
  • MGH/Olink collaboration to investigate the plasma proteomic signatures of COVID-19 positive patients

    Olink Explore 1536 accelerates COVID-19 research and the identification of new biomarkers Olink is immensely proud of our contribution to one of the largest longitudinal COVID-19 studies to date, together with the prestigious Massachusetts General Hospital (MGH). In close collaboration with the team...
  • Multisystem Inflammatory Syndrome in Children with COVID-19

    Insights into a rare but severe complication in children with COVID-19 A study by Petter Brodin’s group at the Karolinska Institiute has looked into an aspect of the COVID-19 pandemic that has perhaps not received enough attention to date. While the large majority of children ...
  • Immune response in mild versus severe COVID-19 infections

    New insights into immune responses in severe COVID-19 A study by researchers at Stanford University and other institutions reveals how the immune system goes awry leading to severe disease during SARS-CoV-2 infections,  and may point to novel therapeutic targets. Taking a systems bi...
  • Systems-level immunomonitoring of severe COVID-19

    June 9, 2020 A study by Petter Brodin’s group at the Karolinska Institute in Stockholm has used a longitudinal, systems-level approach to characterize immune responses at both the cellular and protein level in severe COVID-19, and during the transition from acute disease to th...
  • ACE2 – protein of the moment

    May 20, 2020 New information on the cellular receptor for SARS-CoV-2 Two recent publications have reported important new data on ACE2, the cellular receptor protein for the SARS-CoV-2 virus. Although these studies were not carried out on COVID-19 patients, their findings may be high...
  • COVID-19 Technology Access Framework

    The Broad Institute of MIT and Harvard has joined the “COVID-19 Technology Access Framework” organized by Harvard University, Massachusetts Institute of Technology, and Stanford University. Olink has been acknowledged as a critically important technology within this project and we are proud that ou...
  • ACE inhibition and COVID-19 – a Mendelian Randomization study

    Preprint from new study now available on-line A study from Gill et al has found no evidence to support the hypothesis that the commonly used hypertension drugs known as ACE inhibitors may be of special relevance for COVID-19 patients, potentially increasing severity of the disease via regul...
  • Protein biomarkers of COVID-19 pathophysiology – a collaboration with Radboud UMC in the Netherlands

    Pre-print now available: Olink collaboration with the Division of Infectious Diseases of the Department of Internal Medicine, Radboud University Medical Center, Nijmegen Background Identifying protein biomarkers in patients with SARS-CoV-2 infection is crucial to identify the pathop...